Yes, Rash at Leukine Injection Sites Can Occur Days After Administration
Rash is a well-documented common side effect of Leukine (sargramostim) and can develop at the injection site days after administration. According to the FDA drug label, injection site reactions and other dermatologic disorders are among the most common adverse events associated with Leukine treatment 1.
What the Evidence Shows
FDA-Approved Drug Information
The official Leukine prescribing information explicitly lists rash as one of the most common side effects across multiple patient populations 1:
- Autologous bone marrow transplant patients: Rash is listed among the most common side effects
- Allogeneic bone marrow transplant patients: Rash appears as a common adverse event
- AML patients: Skin reactions are specifically noted as common
The FDA label also warns about serious allergic reactions that can manifest as "skin rash over your entire body" or "hives," though these are more severe presentations requiring immediate medical attention 1.
Comparative Safety Data
Research comparing sargramostim to other colony-stimulating factors confirms that injection site reactions and dermatologic disorders occur significantly more frequently with sargramostim (Leukine) than with filgrastim. One comparative study found injection site reactions and other dermatologic disorders were statistically more common with sargramostim (p<0.05) 2.
Clinical Experience Across Conditions
Multiple studies across different therapeutic areas consistently report injection site reactions with sargramostim:
- Crohn's disease trial: Mild-to-moderate injection-site reactions were more common in the sargramostim group 3
- Parkinson's disease study: Injection-site reactions were documented as sargramostim-associated adverse events during extended treatment 4
Clinical Characteristics
Timing: The rash can appear days after injection, not necessarily immediately. This delayed presentation is consistent with local inflammatory responses.
Severity: Most injection site reactions are mild-to-moderate and do not require treatment discontinuation 3. However, you should monitor for signs of serious allergic reactions.
When to Seek Immediate Medical Attention
Get emergency help if the rash is accompanied by 1:
- Hives or rash over the entire body (not just injection site)
- Trouble breathing or wheezing
- Swelling around mouth or eyes
- Fast heartbeat
- Dizziness or feeling faint
Management Approach
For localized injection site rash:
- This is expected and generally self-limiting
- Document the reaction but continue treatment unless instructed otherwise by your provider
- Contact your healthcare provider if the rash worsens, spreads beyond the injection site, or is accompanied by systemic symptoms
Important caveat: Do not discontinue Leukine on your own. Your healthcare provider needs to assess whether the rash represents a benign local reaction (common and manageable) versus a more serious allergic response (rare but requiring intervention) 1.
The key distinction is between localized injection site reactions (common, expected, generally benign) and systemic allergic reactions (rare, serious, requiring immediate medical attention).